loader image

References

  1. Trelstar® (triptorelin pamoate for injectable suspension) [prescribing information]. Wayne, PA: Verity Pharmaceuticals, Inc. October 2020.
  2. Heyns CF, Simonin M-P, Grosgurin P, Schall R, Porchet HC. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU International. 2003;92:226-231
  3. Bowers CY, Folkers K. Gonadotropin-releasing hormone (GnRH), GnRH superagonists, and GnRH antagonists. In: Munson PL, Mueller RA, Breese GR, eds. Principles of Pharmacology Basics Concepts & Clinical Applications. New York, NY: Chapman & Hall:1995:887-985.
  4. Morgan K, Leighton SP, Millar RP. Probing the GnRH receptor agonist binding site identifies methylated triptorelin as a new anti-proliferative agent. J Mol Biochem. 2012;1:86-98.
  5. Crawford ED, Twardowski PW, Concepcion RS, et al. The impact of late luteinizing hormone-releasing hormone agonist dosing on testosterone suppression in patients with prostate cancer: An analysis of United States clinical data. J Urol. 2020; 203:743-50.
  6. Data on file, Verity Pharmaceuticals, Inc.
  7. Millar RP, Troskie BE, Flanagan CA. Comparative receptor binding affinity and inositol phosphate production potency of D-Leu6 and D-Trp6 GnRH agonist on COS-1 cells transfected with the human GnRH receptor. XII International Congress of Comparative Endocrinology. 1997;559-562.
  8. Harrison GS, et al. Gonadotropin-releasing hormone and its receptor in normal and malignant cells. Endocrine-Related Cancer. 2004; 11(4):725-48.
  9. Teillac P, Heyns CF, Kaisary AV, Bouchot O, Blumberg J. Pharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancer. Horm Res. 2004;62:252-258.
  10. Bertaglia V, Tucci M, Fiori C et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin Genitourin Cancer 2013;11:325-30
  11. Dason S, Allard CB, Tong J, et al. Defining a new testosterone threshold for medical castration: Results from a prospective cohort series. Can Urol Assoc J 2013;7:E263-7.
  12. Kawakami J, Morales A. Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists. Can Urol Assoc J 2013;7:E226-30.
  13. Morote J, et al. Redefining Clinically Significant Castration Levels in Patients With Prostate Cancer Receiving Continuous Androgen Deprivation Therapy. J Urol 2007;178:1290-1295
  14. van der Sluis TM, et al. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. J Urol 2012 May;187(5):1601-6.
  15. Crawford ED, Heidenreich A, Lawrentschuk N, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer and Prostatic Diseases 2018;https://doi.org/10.1038/s41391-018-0079-0

Order Trelstar from CuraScriptSD®

Trelstar can be ordered directly from our national specialty distributor, CuraScriptSD®, which provides next business day delivery and other convenient benefits. Call CuraScriptSD® at 877.599.7748.

If you already have a Trelstar account with CuraScriptSD®, please click here or register at www.curascriptsd.com.

Order Trelstar from AndaMEDS®

Trelstar can be ordered directly from our national specialty distributor, AndaMEDS, which provides next business day delivery and other convenient benefits. Call AndaMEDS at 1.855.468.5649, ext.74453.

If you already have a Trelstar account with AndaMEDS®, please click here or register at www.andameds.com.

Thank you for visiting.

You are now leaving a Verity website. A link to a non-Verity website does not constitute an endorsement of the products or services offered by the non-Verity website, and Verity is not responsible for the content of any non-Verity website.

Healthcare Professionals

The information contained in this website is intended for US Healthcare professionals only.